Related Experiment Video
Updated: Aug 2, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Real-world experiences in migraine therapy with rizatriptan
Dara Jamieson1, F Michael Cutrer, Jerome Goldstein
1University of Pennsylvania, Philadelphia 19486, USA.
Headache
|February 27, 2003
Summary
Rizatriptan effectively treated acute migraine attacks in real-world clinical settings, showing improved pain relief and patient satisfaction compared to previous oral treatments. This study confirms rizatriptan
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Rizatriptan's efficacy in acute migraine is established in clinical trials.
- Real-world effectiveness in typical patient care settings requires further assessment.
Purpose of the Study:
- To evaluate rizatriptan's effectiveness for acute migraine treatment.
- To assess patient satisfaction with rizatriptan in usual clinical practice.
Main Methods:
- Open-label, multicenter study with adult migraineurs.
- Crossover design comparing rizatriptan 10-mg standard tablets and orally disintegrating tablets.
- Patient-reported outcomes via interactive voice response system and baseline questionnaires.
Main Results:
- Patients reported faster pain relief onset (18-23% vs. 16%) with rizatriptan compared to prior oral medications.
- Rizatriptan led to significantly higher rates of no/mild headache (66-67% vs. 37%) and symptom-free status (52-54% vs. 35%) at 2 hours.
- Patient satisfaction was notably higher with rizatriptan (72-74% vs. 53%).
Conclusions:
- Rizatriptan demonstrated superior treatment outcomes in real-world settings compared to previous oral migraine therapies.
- Clinician-selected patient populations showed significant benefits with rizatriptan treatment.
